Aug. 17 at 2:59 PM
Noble Capital Markets Research Report: Cadrenal Therapeutics (
$CVKD) – 2Q26 Reported With Review Of New “Three Pillars” Strategy
2Q26 Reported With Review Of New Strategy and Product Data. Cadrenal reported a 2Q26 loss of
$3.3 million, or $(1.14) per share. The company modified its strategy and plans to develop its products through collaborations, out-licensing agreements, and non-dilutive grants to conserve capital resources. On June 30, 2026, cash and cash equivalents were
$4.2 million, excluding proceeds from the private placement completed July 1.
Read full report here: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-2q26-reported-with-review-of-new-three-pillars-strategy
